0000899243-19-028948.txt : 20191211
0000899243-19-028948.hdr.sgml : 20191211
20191211175036
ACCESSION NUMBER: 0000899243-19-028948
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191209
FILED AS OF DATE: 20191211
DATE AS OF CHANGE: 20191211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ADELMAN DANIEL C MD
CENTRAL INDEX KEY: 0001222037
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 191280538
MAIL ADDRESS:
STREET 1: 23 WOODLEAF AVENUE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94061
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-12-09
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001222037
ADELMAN DANIEL C MD
AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE
CA
94005-1884
0
1
0
0
Chief Medical Officer
Common Stock, $0.0001 par value
2019-12-09
4
M
0
20000
11.45
A
41250
D
Common Stock, $0.0001 par value
2019-12-09
4
S
0
20000
30.0358
D
21250
D
Stock Option (right to buy)
11.45
2019-12-09
4
M
0
20000
0.00
D
2026-06-24
Common Stock
20000
170000
D
The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Includes 11,875 restricted stock units ("RSUs") which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes 9,375 RSUs which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Represents the weighted average sale price for the entire number of shares sold. The sale prices range from $30.00 to $30.14 per share. Information on the actual numbers of shares sold at each sale price can be obtain from the Issuer upon request.
The shares subject to the option vest and become exercisable as to 25% of the total number of shares subject to the option on June 16, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting. date.
Douglas T. Sheehy, as Attorney in Fact for Daniel C. Adelman
2019-12-11